New Rhein Healthcare

Corsair Pharma is focused on developing innovative therapeutic solutions aimed at enhancing the effectiveness of medications for patients. The company is working on a novel prodrug of treprostinil, which is designed to penetrate the skin, enter the bloodstream, and convert quickly to treprostinil in the liver. This approach has the potential to provide effective treatment options with rapid titration for patients suffering from pulmonary arterial hypertension (PAH). By utilizing a once-daily transdermal patch, Corsair Pharma aims to improve patient care and streamline the administration of treatment.

Theranica is a medical device company that specializes in developing wearable solutions for various medical conditions, particularly focusing on migraine treatment. The company utilizes neuromodulation therapy combined with advanced wireless technology to create noninvasive 'smart' patches. These patches are controlled via a smartphone app, allowing for personalized treatment that is both portable and cost-effective. Each patch features a proprietary chip that delivers electrical pulses to modulate sensory nerves beneath the skin, providing temporary or long-term relief from pain. Theranica's innovative approach aims to empower patients in managing their neurological pain effectively and affordably.

Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to conventional BPH treatments, such as medication and surgery. It can be placed in under ten minutes in an office setting, using local anesthesia and without the need for surgical incisions or tissue removal. This approach aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trials have shown promising results, with effective outcomes in relieving blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies at leading medical centers in Europe to validate its device's efficacy and safety.

American Injectables specializes in the manufacturing of sterile injectable drugs, focusing on ready-to-use pre-filled syringes and vials. The company operates a state-of-the-art facility dedicated to alleviating drug shortages by providing efficient solutions that streamline the preparation and administration of medications in various healthcare settings, including hospitals, outpatient centers, and clinics. By offering these ready-to-use products, American Injectables aims to enhance the value for healthcare professionals and pharmacy departments, ultimately improving patient care and resource management.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for peripheral nerve injuries (PNI). Founded in 2016 and headquartered in Louisville, Colorado, with additional offices in Philadelphia and Lafayette, the company aims to improve patient outcomes following acute nerve injuries and reconstructive surgeries. Its product portfolio includes AxoFuse, a nerve repair system that prevents degeneration and atrophy; AxoTrim, a surgical instrument for nerve preparation; AxoBond, which secures repaired nerves during recovery; and NTX-001, a drug-device product for surgical applications. Neuraptive's products are designed to enhance recovery speed and quality for patients, leveraging advanced microsurgical techniques to address the challenges posed by PNI. The company originated from technology developed at the University of Texas, reflecting its commitment to innovation in the field of nerve repair.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for peripheral nerve injuries (PNI). Founded in 2016 and headquartered in Louisville, Colorado, with additional offices in Philadelphia and Lafayette, the company aims to improve patient outcomes following acute nerve injuries and reconstructive surgeries. Its product portfolio includes AxoFuse, a nerve repair system that prevents degeneration and atrophy; AxoTrim, a surgical instrument for nerve preparation; AxoBond, which secures repaired nerves during recovery; and NTX-001, a drug-device product for surgical applications. Neuraptive's products are designed to enhance recovery speed and quality for patients, leveraging advanced microsurgical techniques to address the challenges posed by PNI. The company originated from technology developed at the University of Texas, reflecting its commitment to innovation in the field of nerve repair.

Softhale is a medical device company dedicated to developing Soft Mist Inhalation (SMI) devices designed for the effective delivery of pharmaceutical drugs to the lungs. The company's inhalable therapeutic devices utilize proprietary technical configurations to spray a propellant-free liquid formulation. This advanced delivery method allows medication to navigate the natural curve of the throat, offering patients the opportunity to inhale the medication more naturally. By ensuring that drugs reach deep into the lungs, Softhale aims to enhance respiratory treatments and provide relief for individuals suffering from chronic respiratory conditions.

Chase Pharmaceuticals, established in 2007 and headquartered in Washington D.C., is a specialty pharmaceutical company dedicated to developing treatments for Alzheimer's disease and related neurodegenerative disorders. The company focuses on identifying and clinically developing promising drug candidates, with a particular emphasis on Alzheimer's disease, which currently lacks effective treatments. Chase Pharmaceuticals' lead product, CPC-252, is a transdermal formulation aimed at treating Alzheimer's disease and Parkinsonism dementia. The company operates as a subsidiary of Allergan plc, leveraging its expertise in neuroscience and drug development to advance novel compounds through clinical trials and towards global regulatory approval.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.